| Pharmaceutical Information |
| Drug Name |
Ferumoxytol |
| Drug ID |
BADD_D00889 |
| Description |
Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [A32478].
It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively high dose by rapid intravenous injection [L2181]. |
| Indications and Usage |
Investigated for use/treatment in anemia, kidney disease, and cardiovascular disorders. |
| Marketing Status |
Prescription |
| ATC Code |
Not Available |
| DrugBank ID |
DB06215
|
| KEGG ID |
D04177
|
| MeSH ID |
D052203
|
| PubChem ID |
14789
|
| TTD Drug ID |
D06CTM
|
| NDC Product Code |
0781-3154; 59338-775 |
| Synonyms |
Ferrosoferric Oxide | Oxide, Ferrosoferric | Ferriferrous Oxide | Oxide, Ferriferrous | Magnetite | Feraheme | Ferumoxytol |
|
| Chemical Information |
| Molecular Formula |
Fe3H2O4 |
| CAS Registry Number |
1317-61-9 |
| SMILES |
O[Fe]=O.O[Fe]=O.[Fe] |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
